Prevymis (letermovir) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   32 Trials   32 Trials   1662 News 


«12345678910111213...2425»
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
    Use of Letermovir as Secondary Prophylaxis in Cardiac Transplant Patient, Mismatch for CMV (d+/r-), Resistant to Ganciclovir and Foscarnet (Board #167; Poster Hall) -  Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1464;    
    After achieving VL suppression, in September 2022, the secondary prophylaxis was started with LET 450 mg/day and valganciclovir 900 mg bd, the last one was later discontinued...The patient is currently on prophylaxis with LET and has been asymptomatic during the treatment, with no side effects.Summary Although the use of LET to treat CMV infection is limited in SOT, larger series of cases have documented its successful use when initiated in patients with low/suppressed CMV viremia. In our case the use of LET was effective in obtaining VL suppression for about 1 year in a patient with a CMV strain resistant to both gancyclovir and foscarnet, ensuring the absence of CMV disease.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Tolerability and Clinical Efficacy of Letermovir for Primary Cytomegalovirus Prophylaxis After Heart Transplantation (North Hall) -  Jan 9, 2024 - Abstract #ISHLT2024ISHLT_446;    
    Four (22%) patients developed neutropenia after stopping LET PPX during CMV infection (N=3) or sepsis from a skin and soft tissue infection (N=1).Conclusion LET is well tolerated and shows comparable clinical effectiveness for primary CMV PPX post-HT as compared to a historical, predominantly valganciclovir PPX, cohort. LET PPX was associated with no cases of neutropenia nor breakthrough CMV DNAemia.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Real-life experience in two cases of secondary prophylaxis with letermovir for CMV infection in solid organ transplantation. (Pubmed Central) -  Dec 17, 2023   
    Our study emphasizes that monitoring of CMV disease in the patient and early genotypic detection of resistance mutations are essential when using new antiviral drugs for off-label indication in patients experiencing CMV relapses or not responding to standard antiviral therapy. These cases and the bibliography reviewed can be helpful for other researchers and clinicians working in the field to optimize the use of new treatments for transplant recipients since drug-resistant CMV infection is an important emerging problem even with new developments in antiviral treatment.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Extended duration letermovir in allogeneic hematopoietic stem cell transplant. (Pubmed Central) -  Dec 17, 2023   
    These cases and the bibliography reviewed can be helpful for other researchers and clinicians working in the field to optimize the use of new treatments for transplant recipients since drug-resistant CMV infection is an important emerging problem even with new developments in antiviral treatment. The results of this study suggest that extended duration letermovir prophylaxis may be associated with less CMV reactivation compared to the standard duration of prophylaxis.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Patterns of CMV Infection after Letermovir Withdrawal in Recipients of Post-Transplant Cyclophosphamide Based Transplant (301 (Ballroom Level, Henry B. Gonzalez Convention Center); in-person) -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1323;    
    Taken together, these data suggest that csCMVi after letermovir withdrawal was frequent in patients treated with PT-Cy, despite prolonged exposure. Strategies to boost CMV specific adaptive immunity in patients with persistent hypo-gammaglobulinemia is a logical pathway to reduce csCMVi after letermovir withdrawal.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Exploring Outcomes By Ethnicity in Allogeneic Hematopoietic Cell Transplantation () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1145;    
    Increased EBV reactivations and cGVHD were observed in Black patients and confirmed on MVA, without impact on GRFS. Stratifying by donor source, Black patients received more haploidentical donors; however, in MVA, no discernible effect on CMV reactivations was noted.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    The Clinical Significance of the Drug-Drug Interaction between Letermovir and Voriconazole in Stem Cell Transplantation () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1131;    
    The concomitant use of voriconazole and letermovir in patients undergoing hematopoietic allogeneic stem cell transplant does not result in an increased risk of developing IFIs when compared to patients that received voriconazole alone as prophylaxis. Employing therapeutic drug monitoring of voriconazole levels may still be of clinical utility when approaching the management of suspected or proven IFIs when patients are on concurrent letermovir.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Enhancing Allo-HCT Outcomes with Prophylactic Letermovir Usage  () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1129;    
    The results observed in our cohort abide to the ones reported in literature, with better outcomes for patients in the LTV PP group both on overall analysis and for each risk group category. Prophylactic LTV use improves quality of life, overall survival and decreases the readmission rate.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
    Incidence and Outcomes of Cytomegalovirus Reactivation after Chimeric Antigen Receptor T Cell Therapy () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_946;    
    CMV reactivation is a common complication of CAR T cell therapy in CMV seropositive individuals. Although confirmatory studies are needed, our data shows that immunosuppression, in particular steroids, for management of CAR T cell toxicities is a major risk factor for CMV reactivation, and close monitoring might be indicated in this setting.
  • ||||||||||  Review, Journal:  Anti-CMV therapy, what next? A systematic review. (Pubmed Central) -  Dec 6, 2023   
    Maribavir and letermovir are the latest antivirals to have been developed with other targets...Molecules with a direct action against HCMV include brincidofovir, cyclopropavir and anti-terminase benzimidazole analogs...Immunomodulating molecules such as leflunomide and everolimus have also demonstrated indirect antiviral activity against HCMV and could be an interesting complement to antiviral therapy...All these molecules have shown anti-HCMV potential as monotherapy or in combination with others. These new approaches could be interesting to validate in clinical trials.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
    Journal:  Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant. (Pubmed Central) -  Nov 18, 2023   
    CYP2C19 phenotype and letermovir use were significantly associated with subtherapeutic voriconazole concentrations and may be used to improve voriconazole precision dosing, while further research is needed to clarify the role of ABCG2 in voriconazole dosing. No abstract available
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Actemra IV (tocilizumab) / Roche, JW Pharma
    Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_6376;    
    Letermovir is highly effective completely preventing CMV infections & may contribute to the reduced aGVHD-related mortality recently (as compared to the pre-tocilizumab era), since avoidance of CMV antiviral therapy toxicities greatly facilitates aGVHD prevention & therapy. Given the rapid availability of cryopreserved unmanipulated CB grafts & frequent limitations of URD availability for minority populations, optimized dCBT is a highly attractive curative therapy for acute leukemias & other high-risk myeloid malignancies warranting prospective multi-center investigation.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Ovastat (treosulfan) / Medac, Medexus, Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
    Haploidentical A (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_6375;    
    P2
    The safety and efficacy data of this pilot series of T-haplo-HSCT in SCD reveal that T-haplo-HSCT in advanced stage pediatric and adult SCD patients lacking a MSD is feasible. However, diligent viral monitoring and early treatment of viral reactivation, in particular HHV6 is mandatory as otherwise fatal infections may develop.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Risk Factors for CMV Infection, Including HLA Disparity and Ptcy Transplant in the Era of Letermovir Prophylaxis (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_6374;    
    Patients with PTCy transplant who overcome CMV infection have improved GRFS, possibly due to the increased graft-versus-leukemia effect. Further analysis is required to confirm the difference in the incidence of CMV infection between HLA match and mismatch transplant with PTCy and to assess the significance of late CMV (after Day +100) infection on GRFS.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Ovastat (treosulfan) / Medac, Medexus
    Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_4691;    
    This improvement may be due to one or more changes implemented in recent years, although it is not possible to identify a single factor. These changes were (a) introduction of Frailty testing in all patients (Salas MQ et al.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Low-Dose ATG Has the Same Risk of CMV Reactivation after Allogeneic PBSCT As Ptcy, but Letemovir Is Effective in Preventing CMV Reactivation (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_4494;    
    Post-transplant cyclophosphamide (PTCY) has been spread rapidly worldwide from HLA haploidentical-SCT (Haplo-SCT) to HLA matched-SCT...Letermovir (LTV), a novel anti-CMV agent, was useful for the prevention of CMV reactivation after SCT including Haplo-SCT using PTCY...GVHD prophylaxis in PTCY consisted of CY (40-50 mg/kg on day 3 and 4), tacrolimus (from day 5), and mycophenolate mofetil (from day 5), whereas that in ATG consisted of ATG at a total dose of 2-3 mg/kg around day -2, tacrolimus (from day -1) and short-term methotrexate...LTV was effective for prevention of CMV reactivation in both GVHD prophylaxis methods. CMV breakthrough reactivation may be likely to occur in PBSCT with low-dose ATG compared to that with PTCY even under LTV prophylaxis, and careful CMV monitoring may be required.
  • ||||||||||  Incidence and Outcomes of Cytomegalovirus Reactivation after Chimeric Antigen Receptor T Cell Therapy (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_4462;    
    CMV reactivation is a common complication of CAR T cell therapy in CMV seropositive individuals. Although confirmatory studies are needed, our data shows that administration of immunosuppression, in particular steroids, for management of CAR T cell toxicities is a major risk factor for CMV reactivation, and close monitoring for preemptive therapy or antiviral prophylaxis might be indicated in this setting.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi, Jakafi (ruxolitinib) / Novartis, Incyte
    Implementation of CMV-T-Track (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_2619;    
    Infectious complications decreased 6 months after allo-HCT, and in parallel with discontinuation of immunosuppression and immune reconstitution with no differences according to donor type. Background: Despite Letermovir prophylaxis, reactivation of cytomegalovirus (CMV), requiring close monitoring and preemptive antiviral treatment, remains to be an issue after allogeneic hematopoietic stem cell transplantation (HSCT)...After Alemtuzumab we observed the lowest rate of positive T-Track
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    New Aplastic Anemia Preconditioned with Fludarabine, Thiotepa, Cyclophosphamide, and Anti-Thymocyte Globulin (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_2598;    
    The modified condition regimen consisted of anti-thymoglobulin/antilymphocyte globulin, fludarabine, thiotepa, busulfan and modified low and high-dose cyclophosphamide, mycophenolate mofetil (MMF) and tacrolimus (FK-506)/cyclosporin (CsA) were administered as graft versus host disease (GVHD) prophylaxis after transplantation...Because of 7 patients received the prevention strategy of Letermovir since August 2022, the reactivation rate of cytomegalovirus (CMV) was only 20% and 60% of Epstein-Barr virus (EBV) reactivation, but the CMV diseases and post-transplantation lymphoproliferative disorder (PTLD) were rare. Our study using Thiotepa-based modified haplo-HSCT demonstrated an encouraging result with prolonged survival and reduced complications for aplastic anemia patients.